EGFR and lung cancer: Thus, at least in a group of lung cancers with wild-type EGFR, combining EGFR inhibition with the inhibition of other survival dependent signaling pathways might be a better therapeutic strategy, similar to the successful inhibition of lung cancers with EGFR mutations having acquired resistance [36].